Abstract
Forty-one patients with erythema migrans were enrolled in an open-labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.
Full Text
The Full Text of this article is available as a PDF (137.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alder J., Mitten M., Jarvis K., Gupta P., Clement J. Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. Antimicrob Agents Chemother. 1993 Jun;37(6):1329–1333. doi: 10.1128/aac.37.6.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Berger B. W. Lyme disease. Semin Dermatol. 1993 Dec;12(4):357–362. [PubMed] [Google Scholar]
- Berger B. W. Treatment of erythema chronicum migrans of Lyme disease. Ann N Y Acad Sci. 1988;539:346–351. doi: 10.1111/j.1749-6632.1988.tb31868.x. [DOI] [PubMed] [Google Scholar]
- Buchstein S. R., Gardner P. Lyme disease. Infect Dis Clin North Am. 1991 Mar;5(1):103–116. [PubMed] [Google Scholar]
- Dattwyler R. J., Volkman D. J., Conaty S. M., Platkin S. P., Luft B. J. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet. 1990 Dec 8;336(8728):1404–1406. doi: 10.1016/0140-6736(90)93103-v. [DOI] [PubMed] [Google Scholar]
- Johnson R. C., Kodner C., Russell M., Girard D. In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):33–38. doi: 10.1093/jac/25.suppl_a.33. [DOI] [PubMed] [Google Scholar]
- Massarotti E. M., Luger S. W., Rahn D. W., Messner R. P., Wong J. B., Johnson R. C., Steere A. C. Treatment of early Lyme disease. Am J Med. 1992 Apr;92(4):396–403. doi: 10.1016/0002-9343(92)90270-l. [DOI] [PubMed] [Google Scholar]
- Preac-Mursic V., Wilske B., Schierz G., Süss E., Gross B. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):651–653. doi: 10.1007/BF01968150. [DOI] [PubMed] [Google Scholar]
- Preac-Mursic V., Wilske B., Schierz G., Süss E., Gross B. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):651–653. doi: 10.1007/BF01968150. [DOI] [PubMed] [Google Scholar]
- Weber K., Neubert U., Thurmayr R. Antibiotic therapy in early erythema migrans disease and related disorders. Zentralbl Bakteriol Mikrobiol Hyg A. 1987 Feb;263(3):377–388. doi: 10.1016/s0176-6724(87)80096-2. [DOI] [PubMed] [Google Scholar]